Bioperfectus is officially recognized as the valued membership of IFCC


SHANGHAI, CHINA, August 18, 2022—Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “BioPerfectus”) is pleased to announce that we are now officially recognized as the valued membership of the International Federation of Clinical Chemistry and Laboratory Medicine(IFCC).

By becoming a Corporate Member of IFCC, Bioperfectus will continue to improve our scientific progress and our products' application in the in-vitro diagnostics around the globe under the guidance and standardization of IFCC. By directly involving the global leading organization, we are honored to enhance and promote our expertise and reputation in the global IVD market.

Quick Links

About Bioperfectus


Bioperfectus, a publicly listed company on the Shanghai Stock Exchange (SSE:688399), has been a leading molecular diagnostic solution provider specializing in infectious diseases since 2010. With headquarters in Jiangsu, and subsidiaries in Shanghai, Beijing, Xi'an, Taizhou, Hainan, and Yinchuan, Bioperfectus is a pioneer in the molecular diagnostics market with products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests, and automated laboratory devices. Young and passionate, Bioperfectus is working steadily and firmly to achieve the dream of creating a healthier future for our next generations. For more information, please follow us on LinkedIn or visit

About IFCC

The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is a worldwide, non-political organization for clinical chemistry and laboratory medicine. As such it has a range of roles that include (1) global standard setting in collaboration with other international organizations, (2) supporting its members through scientific and educational endeavour, and (3) providing a series of congresses, conferences and focussed meetings in order for laboratory medicine specialists to meet and present original findings and best practice. To learn more information, please visit 

Media Contact: